CPRX
Market read
The latest filing evidence is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Invalidation: The isolated read changes if CPRX's group or a disclosed connection begins moving with it.
Research brief
The latest filing evidence is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No qualifying adverse evidence was identified; that is not proof there is no downside.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera’s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes…”10-Q · May 11, 2026 ↗
“Generic drug manufacturers were permitted to submit applications for the product challenging our patents starting in 2023 and the FDA is now permitted to approve such ANDA products following the expiration of our orphan drug exclusivity (ODE) on November 26,…”10-Q · May 11, 2026 ↗
Valuation discipline
Price/sales 6.8× · EV/sales 5.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 14 Jul, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for CPRX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
10-Q filed 2026-05-11 against the comparable filing from 2025-05-07.
No thresholded deterioration was identified.
“Total revenues for the three months ended March 31, 2026 and 2025 were as follows (in thousands): For the Three Months Ended March 31, Change 2026 2025 $ % FIRDAPSE® $ 98,859 $ 83,731 15,128 18.1 AGAMREE® 36,713 22,042 14,671 66.6 FYCOMPA® 13,771 35,627 (21,856 ) (61.3 ) Product revenue, net 149,343 141,400 7,943 5.6 License and other revenue 47 21 26 123.8 Total revenues $ 149,390 $ 141,421 7,969 5.6 The increase of approximately $7.9 million in net product revenue when comparing the three months ended March 31, 2026 and 2025 was primarily driven by increases in sales volumes for both FIRDAPSE® and AGAMREE®.”
“Our cash flow activities are summarized as follows (in thousands): For the Three Months Ended March 31, 2026 2025 Net cash provided by operating activities $ 59,587 $ 60,043 Net cash used in investing activities (27 ) — Net cash provided by (used in) financing activities (12,872 ) 3,060 Net increase in cash and cash equivalents $ 46,688 $ 63,103 The decrease in net cash provided by operating activities for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily due to a $12.5 million sales-based milestone payment due upon the achievement of AGAMREE® net revenues of $100 million in a fiscal year, which was achieved in the fourth quarter of 2025 a...”
“2026 compared to the three months ended March 31, 2025 was primarily due to a $12.5 million sales-based milestone payment due upon the achievement of AGAMREE® net revenues of $100 million in a fiscal year, which was achieved in the fourth quarter of 2025 and paid in the first quarter of 2026.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“63 Table of Contents With respect to ANDA filers, in January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc.”
“On October 26, 2012 , the Company entered into a license agreement with BioMarin Pharmaceutical, Inc.”
Depended on by
“In October 2023, the FDA granted AGAMREE (vamorolone), a novel steroid therapy, approval in Duchenne patients aged 2 years and older, and Catalyst Pharmaceuticals, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
CPRX is currently a Follower in the organic co-movement group Digital Services & Software. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CPRX; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.